Clinical Trials Browser

Terminated × Recurrence × ublituximab × Clear all

NCT03778073 2022-08-22

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Phase 1 Terminated

Recurrence, Lymphoma, B-Cell